Early poliovirus vaccine trial promising for recurrent glioblastoma

Share this article:

Attacking glioblastoma brain tumor cells with a modified poliovirus is showing encouraging early results in an ongoing study. The phase I study is seeking to establish the proper dose, and its interim results were reported at the 2013 annual meeting of the American Society of Clinical Oncology in early June in Chicago, Illinois.

The treatment capitalizes on the discovery that cancer cells have an abundance of receptors that work like magnets in drawing the poliovirus, which then infects and kills the cells. The investigational therapy is known as PVSRIPO. It uses an engineered form of the virus that is lethal to cancer cells, while harmless to normal cells. The therapy is infused directly into a patient's tumor. The virus-based therapy also triggers the body's immune system to attack the infected tumor cells.

Preliminary data previewed the results of seven participants enrolled in the study, whose tumors recurred despite traditional treatments for glioblastoma multiforme, which is the most common and aggressive brain tumor.

Of the individuals enrolled in the study, three have responded well to the drug. One patient remains disease-free 12 months after treatment, another 11 months posttreatment and the third is disease-free after five months. With traditional treatment, about half of glioblastoma patients see recurrent tumor growth within 8 weeks.

Two participants in the study did not fare as well; one had recurrent tumor growth after 2 months, and another's condition declined after 4 months. The remaining two patients have been treated in the last 3 and 2 months, respectively, and currently remain disease-free.

"These early results are intriguing," said principal investigator Annick Desjardins, MD, FRCPC, of Duke University School of Medicine in Durham, North Carolina. "Current therapies for glioblastoma are limited because they cannot cross the blood-brain barrier and often do not specifically attack the tumor. This treatment appears to overcome those problems. We are eager to see additional results as we move forward with our study."
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.